Sanofi Genzyme News |

Featured Press Releases

May 16, 2019
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that positive updated data for Libtayo® (cemiplimab-rwlc) in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) will be shared at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in...
May 15, 2019
Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019
Sanofi’s oncology franchise and robust pipeline will be featured at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, delivering against a renewed strategy to address difficult-to-treat and difficult-to-eradicate cancers, including certain types of multiple myeloma, skin cancer, breast...
May 7, 2019
Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
The European Commission has approved Dupixent® (dupilumab) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately...
May 6, 2019
Relapsing MS Patients Who Received Aubagio® (teriflunomide) Experienced a Reduced Risk of Relapse Regardless of Prior Treatment Status in a Post-Hoc Analysis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Patients with relapsing forms of MS who received Sanofi’s Aubagio® (teriflunomide) experienced a significantly reduced risk of relapse irrespective of prior treatment status, according to investigational data from four completed clinical studies. These...

Leadership

Bill Sibold
Executive Vice President and Head of Sanofi Genzyme
Bill joined Sanofi Genzyme in 2011 as Senior Vice President and Head of Multiple Sclerosis, and oversaw the successful launches of its two MS treatments. As Head of Sanofi Genzyme, he leads the business’s efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology. More...

Tweets

Does rheumatoid #arthritis (RA) leave you feeling like you're stuck in a loop of morning stiffness? This… https://t.co/u7UpTASUFs-1 day 9 hours ago

Experiencing ongoing fatigue, joint pain and stiffness despite your current rheumatoid #arthritis (RA) treatment? M… https://t.co/e3b0OMCMvD-2 days 1 hour ago

Many patients living with rheumatoid #arthritis (RA) still experience ongoing symptoms. We go to work each day to a… https://t.co/jqSJrPaXA6-2 days 1 hour ago

Looking forward to it! https://t.co/Mxa1p2r75X-2 days 5 hours ago

@pkmonaghan @Walgreens @BCBSIL Hi Patrick. Sorry you are experiencing difficulties getting your prescription refill… https://t.co/bpyzjb8Uze-3 days 10 hours ago

Search Newsroom

Featured Press Releases

Featured Videos

Leadership

Media Resources

Tweets

Social Media